- Home
- PFD vs GNLX Comparison
PFD vs GNLX Comparison
Compare PFD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- GNLX
- Stock Information
- Founded
- PFD 1990
- GNLX 2001
- Country
- PFD United States
- GNLX United States
- Employees
- PFD N/A
- GNLX N/A
- Industry
- PFD Investment Managers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PFD Finance
- GNLX Health Care
- Exchange
- PFD Nasdaq
- GNLX Nasdaq
- Market Cap
- PFD 143.2M
- GNLX 128.0M
- IPO Year
- PFD N/A
- GNLX 2023
- Fundamental
- Price
- PFD $12.12
- GNLX $4.45
- Analyst Decision
- PFD
- GNLX Strong Buy
- Analyst Count
- PFD 0
- GNLX 4
- Target Price
- PFD N/A
- GNLX $17.75
- AVG Volume (30 Days)
- PFD 33.2K
- GNLX 146.1K
- Earning Date
- PFD 01-01-0001
- GNLX 11-13-2025
- Dividend Yield
- PFD 6.30%
- GNLX N/A
- EPS Growth
- PFD N/A
- GNLX N/A
- EPS
- PFD N/A
- GNLX N/A
- Revenue
- PFD N/A
- GNLX N/A
- Revenue This Year
- PFD N/A
- GNLX N/A
- Revenue Next Year
- PFD N/A
- GNLX N/A
- P/E Ratio
- PFD N/A
- GNLX N/A
- Revenue Growth
- PFD N/A
- GNLX N/A
- 52 Week Low
- PFD $8.53
- GNLX $1.99
- 52 Week High
- PFD $11.18
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- PFD 73.98
- GNLX 66.95
- Support Level
- PFD $11.94
- GNLX $4.17
- Resistance Level
- PFD $12.04
- GNLX $4.45
- Average True Range (ATR)
- PFD 0.08
- GNLX 0.30
- MACD
- PFD -0.01
- GNLX 0.02
- Stochastic Oscillator
- PFD 87.50
- GNLX 80.65
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.